ClinicalTrials.gg

Program

CU06-1004

Also written as “CU06-1004, Single dose” and “CU06-1004, Multiple doses”.

Its studies are mostly in Macular Edema, led by Curacle.

Furthest: phase 2, since Sep 25, 20223 company-led studies, 1 open or runningNext primary completion: Jan 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Curacle31 open or runningphase 2since Sep 25, 2022Mar 5, 2021Jan 1, 2028phase 2 · NCT07459829

Also a collaborator on its studies: kcrn-research-llc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2021First study: phase 1 study in Diabetic Macular EdemaFirst studyNCT04795037 · 81 enrolled · United States
  2. Sep 25, 2022Phase 2 study in Diabetic Macular EdemaNCT05573100 · 67 enrolled · United States, Puerto Rico
  3. Feb 26, 2026Phase 2 study in DMENCT07459829 · 156 planned

Ahead

  1. Jan 1, 2028Primary completion: phase 2 study in DMENCT07459829

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07459829DME2Not yet recruitingJan 1, 2028156
NCT05573100Diabetic Macular Edema · United States, Puerto Rico2CompletedMay 31, 202367
NCT04795037Diabetic Macular Edema · United States1CompletedMar 2, 202281

How it is read

Names in the registry

  • “CU06-1004”, 2 entries
  • “CU06-1004, Single dose”, 1 entry
  • “CU06-1004, Multiple doses”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.